Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 8/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 5/20 | 1.00 |
| ▸ | PRKCA | P17252 | 5/20 | 1.00 |
| ▸ | PRKCH | P24723 | 5/20 | 1.00 |
| ▸ | PRKCI | P41743 | 5/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 5/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 5/20 | 1.00 |
| ▸ | PRKD1 | Q15139 | 5/20 | 1.00 |
| ▸ | PRKCG | P05129 | 4/20 | 1.00 |
| ▸ | PRKCB | P05771 | 4/20 | 1.00 |
| ▸ | PRKCZ | Q05513 | 4/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 7/20 | 0.90 |
| ▸ | KDR | P35968 | 7/20 | 0.90 |
| ▸ | FLT3 | P36888 | 5/20 | 0.84 |
| ▸ | MYLK | Q15746 | 4/20 | 0.84 |
| ▸ | CDK4 | P11802 | 3/20 | 0.84 |
| ▸ | CDK2 | P24941 | 3/20 | 0.84 |
| ▸ | MAP3K11 | Q16584 | 3/20 | 0.84 |
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 0.84 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14825402 | 1.00 | PRKCQ (1.00) | PRKCQPRKD3PRKCAPRKCHPRKCI | |
| SCHEMBL13168059 | 1.00 | PRKCQ (1.00) | PRKCQPRKD3PRKCAPRKCHPRKCI | |
| SCHEMBL16931994 | 1.00 | PRKCQ (1.00) | PRKCQPRKD3PRKCAPRKCHPRKCI | |
| SCHEMBL3747539 | 1.00 | PRKCQ (1.00) | PRKCQPRKD3PRKCAPRKCHPRKCI | |
| SCHEMBL29651606 | 1.00 | PRKCQ (1.00) | PRKCQPRKD3PRKCAPRKCHPRKCI | |
| SCHEMBL14207925 | 1.00 | PRKCQ (1.00) | PRKCQPRKD3PRKCAPRKCHPRKCI | |
| SCHEMBL13246716 | 0.94 | PRKCQ (0.89) | PRKCQPRKD3PRKCAPRKCHPRKCI | |
| K-252A SCHEMBL24112155 | 0.92 | NTRK1 (1.00) | PRKCQPRKD3PRKCAPRKCHPRKCI | |
| K-252A SCHEMBL968886 | 0.92 | NTRK1 (1.00) | PRKCQPRKD3PRKCAPRKCHPRKCI | |
| SCHEMBL21132411 | 0.92 | NTRK1 (0.85) | PRKCQPRKD3PRKCAPRKCHPRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709377-A2 | METHODS OF TREATMENT AND DIAGNOSIS OF PARKINSON'S DISEASE ASSOCIATED WITH WILD-TYPE LRRK2 | Neuron23, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| US-20260011407-A1 | PREDICTIVE BIOMARKERS AND USE THEREOF TO TREAT PARKINSON'S DISEASE | NEURON23 INC (US) | 2026-01-08 | — | — | US | claimed |
| EP-4565328-A1 | PREDICTIVE BIOMARKERS AND USE THEREOF TO TREAT PARKINSON'S DISEASE | Neuron23, Inc. (US) | 2025-06-11 | — | — | EP | claimed |
| CN-120051279-A | Predictive biomarkers and their use for the treatment of parkinson's disease | 神经元23公司 | 2025-05-27 | — | — | CN | claimed |
| WO-2024233854-A2 | METHODS OF TREATMENT AND DIAGNOSIS OF PARKINSON'S DISEASE ASSOCIATED WITH WILD-TYPE LRRK2 | NEURON23, INC. (US) | 2024-11-14 | — | — | WO | claimed |
| WO-2024030504-A1 | PREDICTIVE BIOMARKERS AND USE THEREOF TO TREAT PARKINSON'S DISEASE | NEURON23, INC. (US) | 2024-02-08 | — | — | WO | claimed |
| US-20230392206-A1 | METHODS OF TREATMENT AND DIAGNOSIS OF PARKINSON'S DISEASE ASSOCIATED WITH WILD-TYPE LRRK2 | NEURON23, INC. | 2023-12-07 | — | — | US | claimed |
| CN-116940353-A | Methods for the treatment and diagnosis of parkinson's disease associated with wild-type LRRK2 | 神经元23公司 | 2023-10-24 | — | — | CN | claimed |
| EP-4232024-A1 | METHODS OF TREATMENT AND DIAGNOSIS OF PARKINSON'S DISEASE ASSOCIATED WITH WILD-TYPE LRRK2 | Neuron23, Inc. (US) | 2023-08-30 | — | — | EP | claimed |
| WO-2022093685-A1 | METHODS OF TREATMENT AND DIAGNOSIS OF PARKINSON'S DISEASE ASSOCIATED WITH WILD-TYPE LRRK2 | NEURON23, INC. (US) | 2022-05-05 | — | — | WO | claimed |
| US-20260139289-A1 | CONDITIONAL PRIMER EXTENSION FOR SINGLE-MOLECULE DETECTION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4709377-A2 | METHODS OF TREATMENT AND DIAGNOSIS OF PARKINSON'S DISEASE ASSOCIATED WITH WILD-TYPE LRRK2 | Neuron23, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12533359-B2 | Method for preventing hair loss | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2026-01-27 | — | — | US | disclosed |
| US-20260011407-A1 | PREDICTIVE BIOMARKERS AND USE THEREOF TO TREAT PARKINSON'S DISEASE | NEURON23 INC (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4665868-A2 | METHODS FOR MULTIPLEXED IMAGING AND DETECTION OF TARGETS | President and Fellows of Harvard College (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-3993764-A1 | METHOD FOR PREVENTING HAIR LOSS | Icahn School of Medicine at Mount Sinai (US) | 2022-05-11 | — | — | EP | disclosed |
| WO-2022093685-A1 | METHODS OF TREATMENT AND DIAGNOSIS OF PARKINSON'S DISEASE ASSOCIATED WITH WILD-TYPE LRRK2 | NEURON23, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022076559-A1 | METHODS, COMPOSITIONS, KITS AND SYSTEMS FOR SIGNAL-ON DETECTION OF NEUTRALIZATION TARGETS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-04-14 | — | — | WO | disclosed |
| EP-3974537-A1 | MICROSCOPE-FREE IMAGING | President and Fellows of Harvard College (US) | 2022-03-30 | — | — | EP | disclosed |
| US-20220064699-A1 | CONDITIONAL PRIMER EXTENSION FOR SINGLE-MOLECULE DETECTION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533359-B2 | Method for preventing hair loss | MYLK, MYLK3, MYLK2 | PRKCQ 133/4885PRKD3 202/4885PRKCA 76/4885 |
| US-20260011407-A1 | PREDICTIVE BIOMARKERS AND USE THEREOF TO TREAT PARKINSON'S DISEASE | LRRK2, PARK7, BMP2K | PRKCQ 831/4885PRKD3 938/4885PRKCA 1074/4885 |
| US-20260139289-A1 | CONDITIONAL PRIMER EXTENSION FOR SINGLE-MOLECULE DETECTION | RNGTT, SSU72, CTDSP1 | PRKCQ 1889/4885PRKD3 3706/4885PRKCA 2434/4885 |
| US-20230392206-A1 | METHODS OF TREATMENT AND DIAGNOSIS OF PARKINSON'S DISEASE ASSOCIATED WITH WILD-TYPE LRRK2 | LRRK2, PARK7, PINK1 | PRKCQ 125/4885PRKD3 323/4885PRKCA 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.